Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Treace Medical Concepts (TMCI) Gains from Sales and Divestitures (2022 - 2025)

Treace Medical Concepts' Gains from Sales and Divestitures history spans 4 years, with the latest figure at $7775.0 for Q4 2025.

  • For Q4 2025, Gains from Sales and Divestitures fell 97.73% year-over-year to $7775.0; the TTM value through Dec 2025 reached $7775.0, down 97.73%, while the annual FY2025 figure was $7775.0, 97.73% down from the prior year.
  • Gains from Sales and Divestitures reached $7775.0 in Q4 2025 per TMCI's latest filing, down from $342012.0 in the prior quarter.
  • In the past five years, Gains from Sales and Divestitures ranged from a high of $342012.0 in Q4 2024 to a low of $6223.0 in Q4 2022.
  • Average Gains from Sales and Divestitures over 4 years is $126482.2, with a median of $78847.0 recorded in 2023.
  • Peak YoY movement for Gains from Sales and Divestitures: skyrocketed 2309.11% in 2023, then tumbled 97.73% in 2025.
  • A 4-year view of Gains from Sales and Divestitures shows it stood at $6223.0 in 2022, then surged by 2309.11% to $149919.0 in 2023, then surged by 128.13% to $342012.0 in 2024, then crashed by 97.73% to $7775.0 in 2025.
  • Per Business Quant, the three most recent readings for TMCI's Gains from Sales and Divestitures are $7775.0 (Q4 2025), $342012.0 (Q4 2024), and $149919.0 (Q4 2023).